2216712-66-0

Basic information

• Product Name: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4R)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide
• CAS NO: 2216712-66-0
• Molecular Weight: 597.662
• Mol File: 2216712-66-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 206 - 208°C
• Density: 1.38±0.1 g/cm3(Predicted)
• CAS DataBase Reference: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4R)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4R)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide(2216712-66-0)
• EPA Substance Registry System: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4R)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide(2216712-66-0)

Safety Data

• Hazardous Substances Data: 2216712-66-0(Hazardous Substances Data)

Usage

Uses

Elexacaftor medication used in those that have cystic fibrosis with a f508del mutation.

Upstream product

• 88398-53-2 1,3-dimethyl-1H-pyrazole-4-sulfonamide 
• 89501-93-9 1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride 
• 2229861-17-8 2-chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylic acid 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 1013647-75-0 2,6-dichloropyridine-3-carboxylic acid tert-butyl ester 
• 889940-13-0 3,3,3-trifluoro-2,2-dimethylpropanoic acid 
• 1895296-01-1 3,3,3-trifluoro-2,2-dimethyl-propan-1-ol 
• 5762-40-3 methyl 2,4-dimethyl-4-nitro-pentanoate 

Relevant articles and documents

PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The disclosure provides processes for preparing a compound of Formula (I).

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.